Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Todd Robert Golub, M.D.

Co-Author

This page shows the publications co-authored by Todd Golub and Kimberly Stegmaier.
Connection Strength

3.164
  1. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med. 2007 Apr; 4(4):e122.
    View in: PubMed
    Score: 0.367
  2. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood. 2005 Oct 15; 106(8):2841-8.
    View in: PubMed
    Score: 0.326
  3. Gene expression-based high-throughput screening(GE-HTS) and application to leukemia differentiation. Nat Genet. 2004 Mar; 36(3):257-63.
    View in: PubMed
    Score: 0.295
  4. Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer. Cancer Discov. 2021 Sep; 11(9):2282-2299.
    View in: PubMed
    Score: 0.243
  5. A first-generation pediatric cancer dependency map. Nat Genet. 2021 04; 53(4):529-538.
    View in: PubMed
    Score: 0.242
  6. Selective gene dependencies in MYCN-amplified neuroblastoma include the core transcriptional regulatory circuitry. Nat Genet. 2018 09; 50(9):1240-1246.
    View in: PubMed
    Score: 0.202
  7. CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. J Clin Invest. 2018 01 02; 128(1):446-462.
    View in: PubMed
    Score: 0.192
  8. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014 Nov; 4(11):1326-41.
    View in: PubMed
    Score: 0.154
  9. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 2009 Oct 06; 16(4):281-94.
    View in: PubMed
    Score: 0.109
  10. Identification of AML1-ETO modulators by chemical genomics. Blood. 2009 Jun 11; 113(24):6193-205.
    View in: PubMed
    Score: 0.106
  11. Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. Proc Natl Acad Sci U S A. 2008 Jul 15; 105(28):9751-6.
    View in: PubMed
    Score: 0.100
  12. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell. 2006 Oct; 10(4):321-30.
    View in: PubMed
    Score: 0.089
  13. Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2021 Jul 13; 36(2):109367.
    View in: PubMed
    Score: 0.062
  14. Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q. Cell Rep. 2020 12 15; 33(11):108493.
    View in: PubMed
    Score: 0.059
  15. Small-Molecule and CRISPR Screening Converge to Reveal Receptor Tyrosine Kinase Dependencies in Pediatric Rhabdoid Tumors. Cell Rep. 2019 08 27; 28(9):2331-2344.e8.
    View in: PubMed
    Score: 0.054
  16. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017 Dec; 49(12):1779-1784.
    View in: PubMed
    Score: 0.048
  17. The TEL gene contributes to the pathogenesis of myeloid and lymphoid leukemias by diverse molecular genetic mechanisms. Curr Top Microbiol Immunol. 1997; 220:67-79.
    View in: PubMed
    Score: 0.045
  18. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996 Dec 01; 88(11):4252-8.
    View in: PubMed
    Score: 0.045
  19. The TEL gene and human leukemia. Biochim Biophys Acta. 1996 Aug 08; 1288(1):M7-10.
    View in: PubMed
    Score: 0.044
  20. Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting. Cancer Discov. 2016 08; 6(8):914-29.
    View in: PubMed
    Score: 0.043
  21. Mutational analysis of the candidate tumor suppressor genes TEL and KIP1 in childhood acute lymphoblastic leukemia. Cancer Res. 1996 Mar 15; 56(6):1413-7.
    View in: PubMed
    Score: 0.043
  22. Involvement of the TEL gene in hematologic malignancy by diverse molecular genetic mechanisms. Curr Top Microbiol Immunol. 1996; 211:279-88.
    View in: PubMed
    Score: 0.042
  23. Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2016 Jan; 48(1):101.
    View in: PubMed
    Score: 0.042
  24. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015 Nov; 47(11):1326-1333.
    View in: PubMed
    Score: 0.041
  25. Erratum: Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140044.
    View in: PubMed
    Score: 0.039
  26. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140035.
    View in: PubMed
    Score: 0.039
  27. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. Leuk Res. 2014 Apr; 38(4):430-4.
    View in: PubMed
    Score: 0.036
  28. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11; 499(7457):214-218.
    View in: PubMed
    Score: 0.035
  29. A method for high-throughput gene expression signature analysis. Genome Biol. 2006; 7(7):R61.
    View in: PubMed
    Score: 0.021
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.